Independently developed long-acting anti-HIV drugs approved
Akening® (abbetake for injection), a state-owned new drug independently researched and developed by Frontier Biopharmaceuticals (Nanjing) Co., Ltd., has received approval from the State Drug Administration for approval and was quickly detonated in the medical circle. For a time, the "world's first long-acting HIV-1 fusion inhibitor," and "China's first original anti-Ai'ai new drug," have come together.
As we all know, AIDS is a major infectious disease in the public health field. The full name is Acquired Immunodeficiency Syndrome (AIDS). It is a high-mortality, malignant infectious disease caused by human immunodeficiency virus (HIV) infection. Through sexual contact, blood, mother-to-child transmission.
AIDS is one of the most thorny medical problems in the world. Currently, there is no vaccine that can be effectively prevented, and there are no drugs and treatments that can be effectively cured. The combination therapy with cocktail therapy is currently the main treatment method for controlling HIV in patients worldwide. By using three or more antiviral drugs in combination to treat AIDS, each drug has a different mechanism of action or is directed against HIV. Different parts of the breeding cycle, so as to avoid the drug resistance produced by a single drug, to maximize the inhibition of virus replication, delay the progression of the disease.
The changes in the HIV/AIDS status data show that after the formation and introduction of cocktail therapy in 1995-1996, the morbidity and mortality rate of AIDS declined. In addition, studies have shown that in nearly 70%-80% of patients, the HIV virus declines with the treatment of HAART.
With the deepening of research on the HIV virus, the emergence of innovative anti-Ai drugs such as integrase inhibitors, fusion inhibitors, and co-receptor antagonists has provided more possibilities for the combination therapy of HAART. At present, there are already many cocktail preparations on the market, such as Genvoya in Gilead. The main medicines are eptivir, kebister, emtricitabine, tenofovir alafenamide, and 2NRTIs. , INSTI and pharmacokinetic enhancer; Trizeq jointly developed by GSK and Pfizer, the main drug components are dugweve, abacavir, lamivudine, with 2NRTIs and INSTI. With the continuous improvement of cocktail therapy, the therapeutic effect of AIDS has gradually increased, the side effects have been controlled, and the cost of medication has gradually declined.
From the current market structure of global AIDS drugs, the majority of market share is dominated by six pharmaceutical companies, including Gilead, GSK, Johnson & Johnson, BMS, Merck and Abbott. Its sales volume has increased from 16.3 billion U.S. dollars in 2011 to 23.9 billion U.S. dollars in 2016. Judging from the market share of 6 companies in recent years, since 2011, Gilead’s market share has increased year by year, and in 2016 it has occupied 54% of the global AIDS drugs market; GSK’s market share dropped to 12 in 2012 %, GSK "had stayed for three years" afterwards, and in 2015, the market share of Triumeq, which is a compound preparation, reached a market share of 2.36 billion U.S. dollars and won back 5 percentage points. In 2016, GSK already occupied 20% of the AIDS drug market.
Contrary to the situation of Gilead and GSK, the market share of BMS, MSD, and Abbey during this period was continuously compressed. In 2011, these three companies still had a 34% share of the AIDS drug market, but by 2016 there was only 16% left and the market share was reduced by more than half. Among them, the market share of BMS was the most obvious. It decreased from 19% in 2011 to 8% in 2016, mainly due to the company's business strategy adjustment, which gradually focused on the tumor and immune diseases, while the anti-infective related business became more and more Marginalized.
|
|